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Abstract
Since its discovery in 1898, the renin-angiotensin-aldosterone system (RAAS) 
has been intensely studied in the medical community, which led to important 
breakthroughs concerning the treatment of heart diseases. The main role of RAAS 
is to maintain the circulatory homeostasis, by maintaining the fluid volume. 
Angiotensin II (ANG II) can act on two receptors: angiotensin type 1 and angio-
tensin type 2 (AT1R and AT2R). The effect of AT1R consists in increased sodium 
retention, promotes vasoconstriction (mostly on the efferent arteriole), induces 
sympathetic nervous system activity, determines thirst and promotes the release of 
aldosterone. Abnormal activation of RAAS will determine hypertension and cardiac 
hypertrophy that may lead to heart failure. This is the reason why the pharmacolog-
ical inhibition of this system has proven to induce such a beneficial effect in cardio-
vascular diseases such as hypertension and congestive heart failure. Later studies of 
patients with coronary artery disease revealed that angiotensin-converting enzyme 
(ACE) gene is also involved in the process of atherosclerosis and those mutations in 
its gene account for an increased susceptibility to severe acute coronary events. The 
most common ACE gene mutation is represented by deletions and insertions in the 
16th intron (presence or absence of the 287-bp Alu repeat sequence), resulting in 
three possible genotypes, identified by the length of the fragments: II (490 bp), ID 
(490, 190 bp) and DD (190 bp). Scientific evidence suggests that the D allele plays 
a major role in the determination of coronary artery disease. The next step would 
be to develop new treatment strategies according to the genetic background of each 
patient.
Keywords: renin, angiotensin, aldosterone, sodium retention, hypertension, ACE 
gene mutations, D allele
1. Introduction
The renin-angiotensin-aldosterone system (RAAS) has long been discovered, 
since 1898 by Tigerstedt and Berman, but still possesses many mysteries to be 




The most important result of the activation of this system is the generation of 
angiotensin II (ANG II), which is a biologically active hormone that is produced 
through sequential cleavage of peptides derived from the initial substrate: the mol-
ecule of angiotensinogen. ANG II induces its actions after binding to different types 
of receptors and will induce a wide spectrum of biological reactions that can impact 
almost every system: the immune system, vessels, brain, heart and kidney.
The main role of RAAS is to maintain the circulatory homeostasis, by maintain-
ing the fluid volume. Abnormal activation of RAAS will determine hypertension 
and cardiac hypertrophy that may lead to heart failure. This is the reason why the 
pharmacological inhibition of this system has proven to induce such a beneficial 
effect in cardiovascular diseases such as hypertension and congestive heart failure.
2. Renin-angiotensin-aldosterone system physiopathology
Renin is produced by the epithelioid cells of the juxtaglomerular cells under the 
form of a precursor named preprorenin. Afterwards it may be released as prorenin 
or may be processed to active renin, which will be stored in granules. The release of 
renin granules is the rate-limiting step of the renin-angiotensinogen-aldosterone 
cascade.
The next step consists in the release of angiotensinogen from the liver, which 
will be metabolized by renin, thus liberating angiotensin I (ANG I) [1, 2].
Angiotensinogen is included in the superfamily of Serpin A8 proteins. Serpin 
is a large and diverse superfamily of protease inhibitors and related proteins. It is 
released into the blood stream after removal of the 33-amino acid signal peptide 
and will remain in the circulation for approximately 5 h. However, it remains still 
unclear how much intact angiotensinogen versus catabolized angiotensinogen [the 
so-called des-(Ang I)-Agt] is present in the circulation. There is few data in the 
literature describing the proportions of intact Agt versus des-(Ang I)-Agt in the cir-
culation. Other studies have suggested that des-(Ang I)-Agt may induce angiogen-
esis. Even though the liver is the main source of angiotensinogen synthesis, there are 
some other sources for this enzyme: the brain, heart, kidney, lung, adrenal gland, 
adipose tissue, blood vessels and digestive tube. An independent tissue regulation of 
angiotensinogen levels has also been proven [3–6].
ANG I will be transformed in ANG II due to angiotensin-converting enzyme 
(ACE), which is released from the endothelial cells. The angiotensinogen-convert-
ing enzyme is a dicarboxypeptidase that cleaves two amino acids from ANG I, thus 
generating ANG II (Figure 1).
There have been described two different types of ACE: somatic and testicular, 
which are both a result of the alternative splicing of a single gene. The role of ACE 
in forming ANG II from ANG I is primordial for its biological functions as ANG II is 
the major effector molecule of the RAAS. The ACE acts on other biologically active 
peptides, not only on ANG I, one of the most representative being bradykinin [7–9].
Bradykinin will be transformed into an inactive peptide through the action of 
ACE. This biological pathway for bradykinin metabolism is very significant in vivo. 
The ancient term for ACE is kininase II. As bradykinin promotes vasodilatation and 
induces a natriuretic effect, the pharmacological inhibition of ACE will diminish the 
kininase activity and will subsequently lower the blood pressure. The cleavage of 
ANG II by angiotensin-converting enzyme type 2 produces the heptapeptide angio-
tensin 1-7 (Ang 1-7). This peptide binds to the Mas receptor (MasR) and induces 
downstream vasodilatation, which has an opposing effect of the hypertensive action 
of AT1R signalling. The cardioprotective properties of Ang 1-7 can diminish or 
reverse heart failure and hypertensive cardiac remodelling [10] (Figure 2).
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ACE2 is a monocarboxypeptidase that transforms ANG I into Ang 1-9 which 
is a nonapeptide, and ANG II in Ang 1-7 (a heptapeptide). The discovery of these 
molecules unravels a distinct enzymatic pathway for ANG I and ANG II catabolism 
that will have an antagonist role to RAAS activation.
Ang 1-7 is a biologically active peptide that induces a wide range of effects, 
many of them being antagonist to those caused to Ang II. An endogenous orphan 
receptor, Mas (MasR), was identified in 2003; afterwards this receptor was proved 
to be Ang 1-7 receptor. It also protects cardiovascular function as it enhances 
vasodilatation via elevated release of NO and bradykinin, as well as diminish-
ing the production of reactive oxygen species (ROS). The major effects of Ang 
1-7 are those induced by MasR activation. These effects counterbalance the ones 
induced by ANG II and include the activation of the phosphatidylinositol 3-kinase 
Figure 1. 
The renin-angiotensin-aldosterone cascade [3].
Figure 2. 
ANG II formation [53].
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(PI3K)-Akt-endothelial nitric oxide synthase (eNOS) pathway, the inhibition 
of protein kinase C (PKC)-p38 MAPK pathways and the inhibition of collagen 
expression to limit cardiac fibrosis [11].
Also Ang 1-7 therapies have shown cardioprotective effects in preclinical models 
of non-ischemic and ischemic cardiomyopathy as it inhibited cardiomyocyte 
growth in vitro and diminished the ventricular hypertrophy induced by myocardial 
infarction in vivo. Ang 1-7 diminished the myocardial levels of pro-inflammatory 
cytokines (TNFα and IL-6), thus having a beneficial effect in cardiac inflammation.
Recent studies demonstrated that recombinant human ACE2 generated Ang 1-7 
and Ang 1-9, while recombinant murine ACE2 generated predominantly Ang 1-7.
Ang 1-9 has also proved to be beneficial as it acts on AT2R, thus leading to cardio 
protection. Therefore, the ACE2/Ang 1-7/MasR and ACE2/Ang 1-9/AT2R axes are 
now considered to be physiological antagonists that inhibit the RAAS [10–12].
ANG II can act on two receptors: angiotensin type 1 and angiotensin type 2 
(AT1R and AT2R). The effect of AT1R consists in increased sodium retention, 
promotes vasoconstriction (mostly on the efferent arteriole), induces sympathetic 
nervous system activity, determines thirst and promotes the release of aldosterone 
from the glomerular zone of the suprarenal glands (Figure 3).
The action on AT2R stimulation are antagonist to the one on AT1R as it induces 
vasodilatation and inhibits the inflammatory and fibrotic processes. This receptor 
is prevalent in the foetus; therefore, it has an important role in normal ontogenesis 
but has a minor role in adults [12–16] (Figure 4).
Aldosterone secretion results from the AT1R stimulation and is the final step 
of the RAAS. It is an important regulator of the hydric balance and of sodium and 
potassium exchange. The strongest inducers in aldosterone secretion are ANG II 
and the increased extracellular concentration of potassium, the synthesis of aldo-
sterone being induced by CYP11B2 gene expression. Aldosterone will activate the 
mineralocorticoid receptor, leading to increased reabsorption of natrium and water 
in kidneys and promoting potassium excretion (Figure 3).
Besides the systemic RAAS, a local system found in many tissues, including the 
heart has been described. The local RAAS functions in a dual manner: indepen-
dently and in correlation with systemic RAAS components. This second pathway of 
metabolisation present in the heart consists in ANG II synthesis by the endopepti-
dase chymase. Chymase is a serine protease found in a type of granulocytes called 
mast cells, which are located in the heart interstitium. Mast cells contain granules 
Figure 3. 
The RAAS activation [12].
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that are filled with cytokines and proteases (including chymase). The degranulation 
releases chymase during the inflammatory process via a classically mediated ligand-
dependent pathway. Chymase actions are similar to ACE but with a much higher 
catalytic activity in transforming ANG I into ANG II. Therefore, chymase may be 
in fact a major ANG II-forming enzyme in the human heart. Its role may be linked 
to many pathological processes, such as hypertension, atherosclerosis, vascular 
proliferation, development of cardiomyopathies, myocardial infarction and heart 
failure, as well as cardiac fibrosis [17–20].
A third pathway consists in the action of ACE2 (monocarboxypeptidase 
angiotensin-converting enzyme 2), which is similar to ACE in <50% of amino acidic 
constitution and therefore is unresponsive to the treatment with ACE inhibitors. 
This enzyme transforms ANG I into Ang 1-9 and ANG II into Ang 1-7, thus pro-
moting the synthesis of cardiorenal-protective peptides, through diminishment of 
ANG I and ANG II levels. This pathway may lead to a key role in modulating ANG II 
actions in cardiovascular disease [21].
3. Gene involvement
3.1 ACE gene polymorphisms and heart disease
The implication of gene alterations in the ethiopathogeny of different diseases 
is an important study direction in the later years. The RAAS is not only involved in 
the cardiovascular homeostasy but also in the development of the coronary artery 
disease. It seems that angiotensin-converting enzyme gene mutations have the key 
role in this process.
Figure 4. 
The actions of angiotensin receptors [53].
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ACE gene is found on the long arm of chromosome 17, position 23 (17q23), and 
include 26 exons and 25 introns (Figure 5) [22].
There are several possible mutations of this gene which initiate cardiovascular 
disease. The most common one is represented by deletions and insertions in the 
16th intron (presence or absence of the 287-bp Alu repeat sequence), resulting in 
three possible genotypes, identified by the length of the fragments: II (490 bp), ID 
(490, 190 bp) and DD (190 bp) (Figure 6).
Mutations are determined by collecting 2 ml of blood from the patients, extract-
ing the DNA from the leukocytes, followed by amplification of the genetic material, 
agarose gel electrophoresis in order to separate the fragments and UV light identifi-
cation of coloured fragments according to their length.
Those genotypes interact with the conventional environmental factors and 
influence the severity of the coronary artery disease. Most of the studies have 
demonstrated that the D allele is a risk factor, while the I allele is a protective factor. 
This hypothesis was first formulated by Cambien et al., in the study published 
in Circulation in 1994 [23]. They postulated that D allele is correlated with high 
plasma levels of ACE and that genotypes ID and DD increase the predisposition 
for myocardial infarction. Since then, this theory was largely debated. Guney et al. 
performed a study on 203 patients with acute coronary syndrome or positive func-
tional tests, selected based on the severity of the stenosis (>70%), as revealed by the 
coronary angiography. The control group was formed of 140 patients with nonsig-
nificant coronary stenosis. Results showed a higher prevalence of the D allele in the 
patient group than the control group (p = 0.002), in patients with hyperlipidaemia 
(p = 0.009) and smoking habit (p = 0.004), and a higher number of diseased vessel 
(two/three vessel diseases) (p = 0.002). The conclusion drawn was that D allele 
interacts with conventional risk factor and determines the degree of severity, since 
patients with D allele have higher plasma levels of ACE and are therefore more 
exposed to angiotensin II.
Dhar et al., in a study on 217 patients with coronary disease compared to 255 
control patients (with negative Treadmill test), also found the D allele as an inde-
pendent risk factor in coronary vessel disease (p < 0.05). Most of the ID and DD 
patients were heavy smokers, diabetic and dyslipidemic, suggesting the interaction 
between D allele and risk factors. Another association pointed out by other studies 
is that D allele is more frequent in obese patients. The high levels of angiotensin 
II might lead to disturbances in macronutrient oxidation, causing fat deposits 
and weight gain [24, 25]. Despite the fact that most of the studies focusing on this 
mutation were positive, results are still controversial, since there are a few studies 
which showed negative results. Poorgholi et al. concluded from their 1050 CAD 
patients’ study that I/D polymorphism is not a predisposant factor [26]. Fujimura 
et al. also found no association between ACE gene polymorphism and CAD in 
his study on 1840 patients (947 ischemic patients and 893 healthy controls) [27]. 
Although in some populations, there were no positive correlations between D allele 
and coronary disease; this may be due to geographical differences and ethnical 
differences. In general, D allele seems to be a predisposing factor, and probably the 
severity of the ischemic heart disease (infarction or unstable angina, one/two/three 
Figure 5. 
The ACE gene location [54].
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vessel diseases) depends on the interactions between this mutation and the other 
risk factors: hypertension, diabetes mellitus, obesity, smoking habit and dyslipidae-
mia. In most studies, patients with DD genotype were hospitalized for myocardial 
infarction and had multiple vessel disease and a high exposure to the conventional 
cardiovascular risk factors [28, 29]. The role of D allele in atherosclerosis was gener-
ally studied by measuring and analysing the carotid artery intima-media thickness 
(IMT). Results were statistically significant for high-risk patients, rather than low-
risk patients. Therefore, D variant carriers have an increased risk of atherosclerosis, 
but only if they are also exposed to other genetic or environmental risk factors [30].
The association between ACE gene mutations and hypertension is explained by 
high plasmatic levels of ACE and a consequently increased quantity of ANG II in 
D-allele carriers. However, the predisposition for preeclampsia in D-allele women 
is less understood, and it is just a hypothesis still under debate. Preeclampsia 
implies high blood pressure and proteinuria after 20 weeks of pregnancy. It is the 
consequence of many risk factors, both genetic and environmental, and the RAAS 
may play a key role, since inactivating this system leads to a failure in achieving 
the hypervolemic status needed during pregnancy [31]. The studies on pregnant 
women are rare and often very small, making the available data on this issue very 
inconsistent. Some evidence suggests that it may come as a result of an abnormal 
regulation of the RAAS system and high intrauterine artery resistance [32]. Abedin 
et al., in a study on 296 patients, found no association between I/D polymorphisms 
but demonstrated a positive correlation with another ACE gene mutation, ACE 
rs4343, which was significantly present in the case group versus control group 
(p = 0.0001) [33]. On the other hand, a large meta-analysis including 45 studies 
found that DD and ID pregnant women have a higher risk of pregnancy-induced 
hypertension than II patients (74% D allele in the case group versus 56% D allele in 
the control group) [34]. Still, the large heterogeneity of the included patients lowers 
the force of the obtained results.
Another line of study in this field is represented by the involvement of RAAS 
system in the development of hypertrophic cardiomyopathy. This condition requires 
an anterior interventricular septum larger than 13 mm or a posterior interventricular 
septum larger than 15 mm, in the absence of hypertension and valvular disease. In 
most cases, hypertrophy is asymmetric. The implication of sarcomere protein gene 
mutations in the physiopathology of this disease is widely acknowledged. Later 
studies bring into attention a new puzzle piece in this genetic disorder, suggesting 
Figure 6. 
ACE genotypes: II (490 bp), ID (490, 190 bp) and DD (190 bp) [55].
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that ACE gene may also be involved, since the inhibition of ACE reduces cardiac 
hypertrophy and remodellation post-myocardial infarction [35, 36]. Some studies 
suggest that ACE gene mutations explain the intrafamilial phenotype differences in 
hypertrophic cardiomyopathy, which is considered a monogenic disease [37].
3.2 ACE polymorphism and treatment response
Genetic background often explains the different response to medication of 
patients with the same medical conditions.
“Sodium sensitive” hypertensive patients have certain physiopathological 
particularities: enhanced activity of the sympathetic nervous system, reduced renal 
excretion of sodium, hypersensitivity to vasoconstrictive hormones (adrenaline, 
ANG II) and alterations of the counteracting atrial natriuretic peptide (ANP) [38]. 
The connection between salt and hypertension is still under investigation, and it has 
not been fully explained [39], although it is clear that for some hypertensive patients, 
the mean blood pressure is higher when salt ingestion is increased. Studies focusing 
on determining the frequency of sodium sensitivity in hypertensive patients revealed 
the following distribution: 51% high sodium sensitivity, 33% intermediate sensitivity 
and 16% sodium resistance [40]. Patients with D allele display a higher sensitiv-
ity to dietary sodium intake, and therefore the risk of developing hypertension in 
those patients is increased, when high-sodium/low-potassium diet is associated. 
However, when the diet is low in sodium, the risk between presence and absence of 
D allele seems to be the same [41]. ACE inhibitors represent a gold standard therapy 
for cardiovascular and renal disease. But almost half of the hypertensive patients 
respond to ACE inhibitors alone. Most patients require multiple drug associations. 
Previous studies analysed the role of ACE gene polymorphisms in modulating 
treatment response in different populations around the world, and the results are 
still inconsistent. Heidari et al. in their study on 72 newly diagnosed hypertensive 
patients revealed a stronger response to enalapril and lisinopril in the DD genotype 
than ID (p = 0.03) and II (p = 0.001) [42]. Arnett et al. demonstrated a greater 
response to hydrochlorothiazide in hypertensive women during a 4-week study [43]. 
Results are still controversial. Other studies found no relationship between RAAS 
inhibitory treatment and genetic polymorphisms. For example, the study performed 
by Millions et al. did not link the D allele with a supplementary reduction of blood 
pressure during the treatment with ACE inhibitors [44]. Despite the results of some 
important trials stating that DD patients have a better response to ACE inhibitors, 
those results turn out non-reproducible [45]. Moreover, the pharmacogenomic 
analysis from PROGRESS study (5685 patients) based on the neuroprotective effect 
of perindopril after stroke revealed no implication of the ACE polymorphism on 
the end points [46]. There is also some evidence pointing out a different response 
to hydrochlorothiazide according to this polymorphism and sex: diuretic treatment 
was more efficient in II women and DD men [47]. Others suggested the synergism 
between II, ID and a-adducin Gly/Trp as an even better predictor of response to 
diuretic treatment [47]. The importance of the polymorphism in salt-sensitive 
population, the size of the study population and the ethnic variability may partially 
account for those differences. The differences in the response to ACE inhibitors 
between Caucasians and Africans are overwhelming [48], and this definitely repre-
sents a solid motivation for further investigations in this field. As for the response to 
beta blockers, a very important piece in the hypertension puzzle, it seems that ACE 
gene mutations might also be involved. A randomized controlled trial in hyperten-
sive patients treated with atenolol demonstrated a more important blood pressure 
decrease in patients with an AGT M 235 T or G-6A genotype. But those results were 
not reproducible [45].
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Pharmacogenomics is a new medical field trying to achieve personalized treat-
ments according to our genetic package, in an attempt to obtain better results in the 
treatment-resistant patients. Given that RAAS is a key system in cardiovascular hae-
modynamic, discovering mutations that explain individual differences in efficacy 
and toxicity of various drug categories, as well as designing treatment strategies 
taking genetic data in consideration, will certainly be a revolutionary breakthrough 
in the future, both for hypertension and coronary artery disease.
4. Renin-angiotensin-aldosterone therapeutical blockade
The blockade of RAAS has become a central therapeutic strategy for patients 
with cardiac pathology. The inhibition of RAAS system is realized with modulating 
drugs such as ACEi, angiotensin receptor blockers (ARBs) and mineralocorticoid 
receptor antagonists (MRA) [49, 50].
The direct renin inhibition is obtained upstream of the action of the convert-
ing enzyme and has been well-known for decades. This type of blockade prevents 
the generation of ANG I and subsequently ANG II. The most used drug is named 
aliskiren; it has been evaluated in two clinical heart failure trials: ASTRONAUT and 
ATMOSPHERE. These trials proved that aliskiren failed to reduce cardiovascular 
death or heart failure hospitalization, but it induced a significantly more important 
decrease from baseline in NT-proBNP levels [51].
One of the latest advances in RAAS is represented by the development of 
innovative AT1 receptor blockers which have a dual action, going beyond simple 
antagonism of the binding of ANG II. Similar to the classic ARBs, these molecules 
will act on the superfamily of G-protein-coupled receptors (GPCRs). When GPCRs 
are activated by an agonist, they will determine intracellular dissociation of a 
heterotrimeric G protein into G and G subunits. The result consists in inducing 
second messenger-mediated cellular responses. Other groups of proteins which 
induce specific signalling pathways in a manner that is independent of the protein G 
are represented by the 13-arrestins [49, 51].
Even though efficient blockade of RAAS system can be obtained at different 
levels, the cornerstone therapy remains the use of angiotensin-converting enzyme 
inhibitors (ACEi), ARBs and MRA. RAAS blockade combined with natriuretic 
peptides augmentation is considered to be a revolutionary treatment in heart failure 
patients.
The renin-angiotensin-aldosterone system and the natriuretic peptides have 
a yin/yang relationship that has a great potential in inducing beneficial effects, 
by influencing both systems. The desired effects of the RAAS blockade can be 
enhanced by augmenting the natriuretic peptides activity. Even though the mono-
therapy with neprilysin inhibitors has failed to prove efficiency in heart failure 
patients, the association with a RAAS blocker has overcome the disappointing 
results, and even more, it has proven to be one of the most promising therapies in 
patients with different types of heart failure [52].
5. Conclusions
The renin-angiotensin-aldosterone system is a key piece in the puzzle of cardio-
vascular homeostasis and disease. Therapeutical targeting of this system at different 
levels represents an important medical breakthrough. The observation that patients 
with the same condition and exposure to risk factors may have different disease 
evolutions and responses to treatment led to genetic studies and to the discovery 
Renin-Angiotensin System
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of the importance of ACE D allele in the determinism of coronary artery disease, 
arterial hypertension and hypertrophic cardiomyopathy. Therefore, developing 
treatment strategies according to the specific genetic pattern of the patient is the 
next step in medical evolution.
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